Figure 5
Figure 5. Acquisition of higher T-cell stimulating activities by Daf−/− macrophages and DCs in vivo requires C3 and C5aR. (A) Thioglycollate-elicited peritoneal macrophages from Daf−/− mice, but not Daf−/−/C3−/− or Daf−/−/C5aR−/− mice, were more potent than similarly harvested WT macrophages in stimulating OT-II CD4+ T cells as measured by IFN-γ production. *P < .05 comparing with the Daf−/− group. (B) Splenic DCs from LPS-treated Daf−/− mice, but not similarly treated Daf−/−/C3−/− or Daf−/−/C5aR−/− mice or Daf−/− mice pre-treated with a C5aR antagonist (C5a-ant in vivo), were more potent than WT mouse DCs in stimulating OT-II CD4+ T cells as measured by IFN-γ production. *P < .05 comparing with the Daf−/− group. In contrast, addition of the C5aR antagonist to the cell culture of Daf−/− DCs and OT-II CD4+ T cells (C5a-ant in vitro) had no effect. NS indicates not significant. P > .05 comparing with the Daf−/− group.

Acquisition of higher T-cell stimulating activities by Daf−/− macrophages and DCs in vivo requires C3 and C5aR. (A) Thioglycollate-elicited peritoneal macrophages from Daf−/− mice, but not Daf−/−/C3−/− or Daf−/−/C5aR−/− mice, were more potent than similarly harvested WT macrophages in stimulating OT-II CD4+ T cells as measured by IFN-γ production. *P < .05 comparing with the Daf−/− group. (B) Splenic DCs from LPS-treated Daf−/− mice, but not similarly treated Daf−/−/C3−/− or Daf−/−/C5aR−/− mice or Daf−/− mice pre-treated with a C5aR antagonist (C5a-ant in vivo), were more potent than WT mouse DCs in stimulating OT-II CD4+ T cells as measured by IFN-γ production. *P < .05 comparing with the Daf−/− group. In contrast, addition of the C5aR antagonist to the cell culture of Daf−/− DCs and OT-II CD4+ T cells (C5a-ant in vitro) had no effect. NS indicates not significant. P > .05 comparing with the Daf−/− group.

Close Modal

or Create an Account

Close Modal
Close Modal